@Article{Tomaszewski2003,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="2",
number="2",
year="2003",
title="Progestins in hormonal replecement therapy - new perspectives",
abstract="In the last years there has been an extraordinary development in the synthesis of new progestins. The action of progestins is a function of many factors: its structure, activity, affinity to the progesterone or to the other steroids receptors, the target tissue considered, dose, and metabolic transformation. Several risks are attributed to progestins as a class-effect; however, progestogens used in hormonal replacement therapy have varying pharmacological properties and do not induce the same side effects. Newly synthesized progestins (19-norprogesterone and 18\α-spironolactone derivatives) do not bind to the androgen receptor and do not exert an androgenic side effect. Selection molecules having no estrogenic, androgenic or glucocorticoid effects should allow a larger use of the progestins in HRT without any major drawback.",
author="Tomaszewski, Jacek
and Baranowski, Włodzimierz",
pages="12--17",
url="https://www.termedia.pl/Progestins-in-hormonal-replecement-therapy-new-perspectives,4,309,1,1.html"
}